Related Experiment Videos
Pergolide-induced pleuropulmonary fibrosis.
G S Bleumink1, M van der Molen-Eijgenraam, J H Strijbos
1Drug Safety Unit, Inspectorate for Healthcare, The Hague, The Netherlands.
Clinical Neuropharmacology
|November 1, 2002
Summary
Ergot alkaloids, like pergolide, can cause rare but serious pleuropulmonary fibrosis. Early diagnosis of this irreversible condition is crucial for minimizing patient damage.
Area of Science:
- Pharmacology
- Pulmonology
- Toxicology
Background:
- Ergot alkaloids are associated with rare adverse effects.
- Pleuropulmonary fibrosis is a recognized complication.
- Serosal fibrosis can manifest in various forms.
Observation:
- Four patients developed pleural and/or pulmonary fibrosis during pergolide treatment.
- Eighty-seven cases with serosal fibrosis symptoms were analyzed.
- Fibrosis can affect the pleura, lungs, and retroperitoneum.
Findings:
- Pleuropulmonary fibrosis is a serious and often irreversible adverse effect of ergot alkaloids.
- Pergolide treatment was linked to these fibrotic conditions in the reported cases.
- Serosal fibrosis symptoms were observed in a significant number of patients.
Implications:
- Increased awareness of ergot alkaloid-induced fibrosis is needed.
- Early diagnosis can help minimize permanent patient damage.
- Prompt identification and management are key to better patient outcomes.